Patients with antineutrophil cytoplasmic antibodies associated vasculitis in remission are hypercoagulable

Journal of Rheumatology

Volumn 40, Issue 12, 2013, Pages 2042-2046

  Hilhorst, Marc ^a   Winckers, Kristien ^b   Wilde, Benjamin ^a   Van Oerle, René ^b   Ten Cate, Hugo ^b   Tervaert, Jan Willem Cohen ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b Laboratory for Clinical Thrombosis and Hemostasis   (Netherlands)

Author keywords

ANCA associated vasculitis; Endogenous thrombin potential; Thrombosis

Indexed keywords

ANTIVITAMIN K; AZATHIOPRINE; BLOOD CLOTTING FACTOR 8; D DIMER; FIBRINOGEN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PROTEIN C; PROTEIN S; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; ANCA ASSOCIATED VASCULITIS; ARTICLE; BLOOD ANALYSIS; BLOOD CLOTTING PARAMETERS; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOGENOUS THROMBIN POTENTIAL; ENDOTHELIAL DYSFUNCTION; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HYPERCOAGULABILITY; IMMUNOSUPPRESSIVE TREATMENT; MALE; MEDICAL HISTORY; MONOTHERAPY; PRIORITY JOURNAL; REMISSION; VENOUS THROMBOEMBOLISM;

ANCA ASSOCIATED VASCULITIS; ENDOGENOUS THROMBIN POTENTIAL; THROMBOSIS;

ADULT; AGED; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; FACTOR VIII; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; FOLLOW-UP STUDIES; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; PROTEIN C; PROTEIN S; REMISSION INDUCTION; RISK FACTORS; THROMBIN; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

EID: 84889023412     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.130200     Document Type: Article

References (22)

1. Wilde B, Van Paassen P, Witzke O, Tervaert JW. New pathophysiological insights and treatment of ANCA-associated vasculitis. Kidney Int 2011;79:599-612.
2. Merkel P, Lo G, Holbrook J, Tibbs AK, Allen NB, Davis JC Jr, et al. Brief communication: High incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med 2005;142:620-6.
3. Weidner S, Hafezi-Rachti S, Rupprecht H. Thromboembolic events as a complication of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2006;55:146-9.
4. Stassen P, Derks R, Kallenberg C, Stegeman CA. Venous thromboembolism in ANCA-associated vasculitis - incidence and risk factors. Rheumatology 2008;47:530-4.
5. Allenbach Y, Seror R, Pagnoux C, Teixeira L, Guilpain P, Guillevin L, et al. High frequency of venous thromboembolic events in Churg-Strauss syndrome, Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retrospective study on 1130 patients. Ann Rheum Dis 2009; 68:564-7.
6. Hansson P, Welin L, Tibblin G, Eriksson H. Deep vein thrombosis and pulmonary embolism in the general population. 'The Study of Men Born in 1913'. Arch Int Med 1997;157:1665-70.
7. Springer J, Villa-Forte A. Thrombosis in vasculitis. Curr Opin Rheumatol 2013;25:19-25.
8. Borissoff J, Spronk H, Ten Cate H. The Hemostatic System as a Modulator of Atherosclerosis. N Engl J Med 2011;364:1746-60.
9. Jennette JC, Falk RJ, Bacon P, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65:1-11.
10. Damoiseaux JGMC, Slot MC, Vaessen M, Stegeman CA, Van Paassen P, Tervaert JW. Evaluation of a new fluorescent-enzyme immuno-assay for diagnosis and follow-up of ANCA-associated vasculitis. J Clin Immunol 2005;25:202-8.
11. Hellmich B, Flossmann O, Gross WL, Bacon P, Cohen-Tervaert JW, Guillevin L, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007;66:605-17.
12. Damoiseaux J, Peeters L, Hupperts R, Boreas A, ten Cate H, Tervaert JW. Prevalence of anticardiolipin antibodies in patient cohorts with distinct clinical manifestations of the antiphospholipid syndrome. Ann N Y Acad Sci 2009;1173:146-51.
13. Dielis A, Castoldi E, Spronk H, van Oerle R, Hamulyak K, Ten Cate H, et al. Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. J Thromb Haemost 2008;6:125-31.
14. Dielis A, Balliel W, Van Oerle R, Hermens WT, Spronk HM, Ten Cate H, et al. Thrombomodulin-modified thrombin generation after in vivo recombinant factor VIII treatment in severe hemophilia A. Haematologica 2008;93:1351-7.
15. Maurissen L, Castoldi E, Simioni P, Rosing J, Hackeng TM. Thrombin generation-based assays to measure the activity of the TFPI-protein S pathway in plasma from normal and protein S-deficient individuals. J Thromb Haemost 2010;8:750-8.
16. Castoldi E, Rosing J. Thrombin generation tests. Thromb Res 2011;127 Suppl 3:S21-S5.
17. Machlus KR, Colby EA, Wu JR, Koch GG, Key NS, Wolberg AS. Effects of tissue factor, thrombomodulin and elevated clotting factor levels on thrombin generation in the calibrated automated thrombogram. Thromb Haemost 2009;102:936-44.
18. Hergesell O, Andrassy K, Nawroth P. Elevated levels of markers of endothelial cell damage and markers of activated coagulation in patients with systemic necrotizing vasculitis. Thromb Haemost 1996;75:892-8.
19. Constans J, Conri C. Circulating markers of endothelial function in cardiovascular disease. Clin Chim Acta 2006;368:33-47.
20. Meesters E, Hansen H, Spronk H, Hamulyak K, Rosing J, Rowshani AT, et al. The inflammation and coagulation cross-talk in patients with systemic lupus erythematosus. Blood Coagul Fibrinolysis 2007;18:21-8.
21. Bautz D, Preston G, Lionaki S, Hewins P, Wolberg AS, Yang JJ, et al. Antibodies with dual reactivity to plasminogen and complementary PR3 in PR3-ANCA vasculitis. J Am Soc Nephrol 2008;19:2421-9.
22. Berden A, Nolan S, Morris H, Bertina RM, Erasmus DD, Hagen EC, et al. Anti-plasminogen antibodies compromise fibrinolysis and associate with renal histology in ANCA-associated vasculitis. J Am Soc Nephrol 2010;21:2169-79.